scholarly journals A Comparison of the Prevalence of the Metabolic Syndrome among Sri Lankan Patients with Type 2 Diabetes Mellitus Using WHO, NCEP-ATP III, and IDF Definitions

2018 ◽  
Vol 2018 ◽  
pp. 1-8 ◽  
Author(s):  
H. M. M. Herath ◽  
N. P. Weerasinghe ◽  
T. P. Weerarathna ◽  
A. Amarathunga

Background. Presence of metabolic syndrome (MetS) in patients with type 2 diabetes mellitus (type 2 DM) increases the risk of cardiovascular morbidity and mortality. Therefore, recognition of MetS in type 2 DM is important in initiating the appropriate preventive and therapeutic measures. The commonly used definitions have similarities and discrepancies. Aims of this study was to investigate the prevalence of MetS among patients with type 2DM using all three well known (WHO, IDF, and NCEP-ATP III) definitions and to identify the concordance and the difference of these three definitions. Methods. This cross-sectional study included patients with type 2 DM who were followed up at the regional diabetes centre in Galle, Sri Lanka. A total of 2913 type 2 DM patients were recruited by convenient sampling method, and their clinical and biochemical data were collected. Results. The mean age (SD) of the sample was 49.9 (10.2) years and the mean duration of diabetes was 5.04 (5.71). Prevalence of MetS was highest by WHO (70%) followed by IDF (44%) and NCEP-ATP III (29%) definitions. The prevalence was significantly higher in women according to all three definitions, and the difference was most marked with NCEP-ATP III and IDF definitions. Around 25% were identified as having MetS by all three definitions whereas around 45% were recognized with MetS by two definitions. While concordances between WHO with IDF (0.37, p < 0.001) and NCEP-ATP III (0.24, p < 0.001) criteria were poor, they were average (0.53, p < 0.001) between NCEP-ATP III and IDF criteria. Conclusions. The prevalence of MetS among patients with type 2 DM can significantly be varied based on the definition used and the three definitions of MetS recognized different set of individuals. The highest prevalence of MetS was observed with WHO (70.6%) whereas lowest was observed with NCEP-ATP III definition.

2016 ◽  
Vol 9 (1) ◽  
pp. 26
Author(s):  
Mahbooba Akhter ◽  
Afsana Ahmed ◽  
Mahbubor Rahman ◽  
Roksana Malek ◽  
Azmeri Alam ◽  
...  

<p><strong>B</strong><strong>ackground</strong><strong>: </strong>The metabolic syndrome is driving twin global epidemics; type 2 diabetes mellitus and cardiovascular disease. There is an overwhelming moral, medical, and economic imperative to identify those individuals with metabolic syndrome. Regarding this issue, non obese individuals are given less attention and ultimately situation becomes grievous therefore.</p><p><strong>Ob</strong><strong>j</strong><strong>ective</strong><strong>: </strong>To assess the prevalence of metabolic syndrome in non–obese newly detected type 2 DM patient. Method: This cross sectional analytical study was carried out in the department of Biochemistry, Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh. Total 209 cases (165 male &amp; 44 female) were selected from BIRDEM. Statistical analysis and data management were carried out using the SPSS (Version 12.0).</p><p><strong>R</strong><strong>esult</strong><strong>: </strong>In this study, prevalence rates of metabolic syndrome were 60.3% (53.3% male, 86.4% female), 58.9% (57.0% male, 65.9% female) and 26.3% (15.8% male, 65.9% female) according to modified National Cholesterol Education Program Adult Treatment Panel III (NCEP-ATP III), modified WHO &amp; IDF criteria respectively.</p><p><strong>Conclusion</strong><strong>: </strong>Prevalence of metabolic syndrome in non-obese newly detected Type 2 DM is very high &amp; Prevalence of metabolic syndrome in non-obese newly detected Type 2 DM found significantly higher in female than male. Adequate realistic steps of preventive strategy are of urgent need to combat this high prevalence of metabolic syndrome in non-obese diabetic people.</p>


2020 ◽  
Vol 92 (5) ◽  
pp. 110-118 ◽  
Author(s):  
T. S. Panevin ◽  
M. S. Eliseev ◽  
M. V. Shestakova ◽  
E. L. Nasonov

Currently, only two drugs for reducing uric acid (UA), allopurinol and febuxostat, are registered in the Russian Federation, but their use does not allow to achieve the target level of UA in all cases. According to the results of numerous randomized trials, hyperuricemia and gout are associated with the corresponding components of the metabolic syndrome, including diabetes mellitus. The influence of factors is due to the need to search for new drugs that have a complex effect on several components of metabolic syndrome at once. Potentially attractive in this regard is a new group of drugs for the treatment of type 2 diabetes mellitus inhibitors of the sodium-glucose cotransporter of type 2, which, in addition to the main hypoglycemic actions, showed positive effects on the cardiovascular system, kidneys, as well as lowering UA.


Author(s):  
K. Satya Anand ◽  
Ruksana . ◽  
Anand Acharya

Background: All these metabolic derangements exist for many years in the asymptomatic phase of type 2 diabetes and they predispose to development of complications even before clinical diagnosis. Metabolic syndrome is considered to be a precursor of type 2 diabetes. Present study is primarily aimed to study the prevalence of micro vascular complications and metabolic syndrome in newly diagnosed type 2 diabetes mellitus patients of low socio-economic group.Methods: This is a cross sectional prospective study conducted in the dept. of general medicine Konaseema institute of medical science Amalapuram, Andhra Pradesh, India from November 2016 to October 2018. Based on exclusion and inclusion criteria 103 patients were enrolled for this study. Various parameters like age, sex, body mass index, waist circumference, lipid profile, systolic and diastolic blood pressure, neuropathy, nephropathy and retinopathy was measured.Results: The mean age of the patient was 48±10.0 years. Fasting and 2 hours OGTT was 174.6±46.8 mg/dl and 255.6±75.6 mg/dl. The mean of total cholesterol was 204.7±41.9 (mg/dl), Triglycerides was 218±83.4 (mg/dl) and HDL was 44±5.3 (mg/dl). Symptomatic neuropathy constituted 35.6% in 51-60 age group and 27.1% in 31-40 and 41-50 age groups. Objective neuropathy constituted highest (36.6%) in 51-60 age group. Retinopathy constituted highest (60%) in 51-60 age group and nephropathy constituted 26.3 % in 21-30 and 51-60 age groups.Conclusions: Prevalence of microvascular complications in newly diagnosed diabetics of low socioeconomic group were as follows: symptomatic neuropathy-57.3%, objective neuropathy-39.8%, retinopathy-4.9%, nephropathy-18.4%. These were similar to published studies from general population from the same geographical area.


Sign in / Sign up

Export Citation Format

Share Document